Literature DB >> 21904962

The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas.

Sung Gwe Ahn1, Sung Hoon Kim, Tae Joo Jeon, Ho Jin Cho, Sae Byeol Choi, Mi Jin Yun, Jong Doo Lee, Kyung Sik Kim.   

Abstract

PURPOSE: (18)F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) scan reflects tumor differentiation and predicts clinical outcome in patients with hepatocellular carcinoma (HCC). We investigated the correlation of PET scans with tumor differentiation and early tumor recurrence (time-to-recurrence <1 year).
METHODS: We reviewed the medical records of 93 patients with HCC who underwent curative resection at our hospital from August 2004 through December 2008. PET scans were performed preoperatively, and the maximum standardized uptake value of the tumor (SUV(tumor)) and the tumor-to-non-tumor SUV ratio (TNR) were calculated from FDG uptake.
RESULTS: Twenty-six (27.9%) had recurrences and 12 of them (46.2%) had early recurrences. SUV(tumor) and TNR correlated strongly with tumor differentiation (p < 0.001). Early recurrence-free and the overall survival rates in the low TNR group (TNR <2.0) were higher than in the high TNR group (TNR ≥2.0) (p = 0.015, p = 0.013). According to univariate analysis, predictors of early tumor recurrence were large tumor size (≥5 cm), high TNR (≥2), high SUV(tumor) (≥4), and high Edmoson-Steiner grade. However, on multivariate analysis, none of the examined factors were statistically significant independent predictor.
CONCLUSION: PET scans reflect tumor differentiation in HCCs. Because high TNR (TNR ≥2) and SUV(tumor) (SUV ≥4) were these cutoff point significant predictors in univariate analysis, future studies with more statistical power are needed to assess the significance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21904962     DOI: 10.1007/s11605-011-1660-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  37 in total

1.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

Authors:  Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Peter Vandenberghe; Johan Maertens; Guy Bormans; José Thomas; Jan Balzarini; Christine De Wolf-Peeters; Luc Mortelmans; Gregor Verhoef
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

2.  Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

Authors:  S Shiomi; S Nishiguchi; H Ishizu; Y Iwata; N Sasaki; A Tamori; D Habu; T Takeda; S Kubo; H Ochi
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

3.  Postoperative recurrence of hepatocellular carcinoma.

Authors:  T Nagao; S Inoue; F Yoshimi; M Sodeyama; Y Omori; T Mizuta; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis.

Authors:  J Belghiti; Y Panis; O Farges; J P Benhamou; F Fekete
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

6.  Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma.

Authors:  T Matsumata; T Kanematsu; K Takenaka; Y Yoshida; T Nishizaki; K Sugimachi
Journal:  Hepatology       Date:  1989-03       Impact factor: 17.425

7.  Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.

Authors:  S Okazumi; K Isono; K Enomoto; T Kikuchi; M Ozaki; H Yamamoto; H Hayashi; T Asano; M Ryu
Journal:  J Nucl Med       Date:  1992-03       Impact factor: 10.057

8.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.

Authors:  T Torizuka; N Tamaki; T Inokuma; Y Magata; S Sasayama; Y Yonekura; A Tanaka; Y Yamaoka; K Yamamoto; J Konishi
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

9.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

10.  FDG-PET. A possible prognostic factor in head and neck cancer.

Authors:  W Halfpenny; S F Hain; L Biassoni; M N Maisey; J A Sherman; M McGurk
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  15 in total

1.  18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Myeong Jun Song; Si Hyun Bae; Sung Won Lee; Do Sun Song; Hee Yeon Kim; Ie Ryung Yoo; Joon-Il Choi; Young June Lee; Ho Jong Chun; Hae Giu Lee; Jong Young Choi; Seung Kew Yoon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

2.  Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.

Authors:  Jeong Won Lee; Sang Hyun Hwang; Hyun Jeong Kim; Dongwoo Kim; Arthur Cho; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-11       Impact factor: 9.236

3.  Long-Term Outcome After Resection of Huge Hepatocellular Carcinoma ≥ 10 cm: Single-Institution Experience with 471 Patients.

Authors:  Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Sung-Gyu Lee
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

4.  The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients.

Authors:  Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-05-09       Impact factor: 3.452

5.  Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors.

Authors:  Nandakumar Menon; Mark Mandelkern
Journal:  Dig Dis Sci       Date:  2022-07-30       Impact factor: 3.487

6.  Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Authors:  Satoshi Takeuchi; Eric M Rohren; Reham Abdel-Wahab; Lianchun Xiao; Jeffrey S Morris; Homer A Macapinlac; Manal M Hassan; Ahmed O Kaseb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-12       Impact factor: 9.236

7.  (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma.

Authors:  E Simoneau; M Hassanain; A Madkhali; A Salman; C G Nudo; P Chaudhury; P Metrakos
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

8.  Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.

Authors:  Seung Hyup Hyun; Jae Seon Eo; Jeong Won Lee; Joon Young Choi; Kyung-Han Lee; Sae Jung Na; Il Ki Hong; Jin Kyoung Oh; Yong An Chung; Bong-Il Song; Tae-Sung Kim; Kyung Sik Kim; Dae Hyuk Moon; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-02       Impact factor: 9.236

Review 9.  Prognostic factors for hepatocellular carcinoma recurrence.

Authors:  Antonio Colecchia; Ramona Schiumerini; Alessandro Cucchetti; Matteo Cescon; Martina Taddia; Giovanni Marasco; Davide Festi
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

10.  Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.

Authors:  Min Jin Kim; Young Seok Kim; Youn Hee Cho; Hee Yoon Jang; Jeong-Yeop Song; Sae Hwan Lee; Soung Won Jeong; Sang Gyune Kim; Jae Young Jang; Hong Su Kim; Boo Sung Kim; Won Hyung Lee; Jung Mi Park; Jae Myung Lee; Min Hee Lee; Deuk Lin Choi
Journal:  Korean J Intern Med       Date:  2015-04-29       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.